Investor Updates

08. Februar 2012
FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License ... mehr

08. Februar 2012
Roche disappointed by the actions of Illumina, Inc.'s Board of Directors
Roche released the following statement in response to the announcement by Illumina, Inc. that its Board of Directors has recommended ... mehr

01. Februar 2012
Full reconciliation of Chugai 2011 results into IFRS
Following the publication of Chugai’s official 2011 results, Roche offers this investor update which reconciles these ... mehr

01. Februar 2012
Roche in 2011: Strong results and positive outlook
Group sales rise 2% 1 (-10% in Swiss francs; +6% in US dollars), excluding Tamiflu; Significant foreign exchange impact of ... mehr

31. Januar 2012
Roche to nominate slate of independent directors for election at Illumina, Inc.'s 2012 annual meeting
Roche announced today that it has provided notice to Illumina, Inc. (NASDAQ: ILMN) that it will nominate a slate of highly ... mehr

30. Januar 2012
FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma
Roche today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for adults ... mehr

27. Januar 2012
Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash
Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals, life science tools and diagnostics, ... mehr

27. Januar 2012
Roche responds to adoption of shareholder rights plan by Illumina Board of Directors
Roche today responded to an announcement from Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has adopted a shareholder ... mehr

26. Januar 2012
Avastin-based regimen extends survival when continued beyond initial treatment in patients with metastatic colorectal cancer
First randomised phase III trial evaluating continued use of Avastin with chemotherapy after disease progression meets primary ... mehr

25. Januar 2012
Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics
Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. (NASDAQ:ILMN) for $44.50 per ... mehr

18. Januar 2012
Reminder: Invitation to Roche's Full Year Results for 2011
Roche will publish its Full Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 1st February 2012 at ... mehr

11. Januar 2012
Roche receives clearance from the U.S. Food and Drug Administration for the new Accu-Chek Nano SmartView blood glucose monitoring system
Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Nano ... mehr

03. Januar 2012
Invitation to Roche's Full Year Results for 2011
Roche will publish its Full Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 1st February 2012 at ... mehr

23. Dezember 2011
Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer
Roche announced today that the European Commission has approved Avastin (bevacizumab) in combination with standard chemotherapy ... mehr

16. Dezember 2011
Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF mutation-positive metastatic melanoma
Roche, today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted ... mehr

12. Dezember 2011
First head to head study shows higher response rates for GA101 vs. MabThera/Rituxan without appreciable differences in safety in common type of blood cancer
Separate study indicates that GA101 is highly effective in combination with chemotherapy. Roche announced today that its investigational ... mehr

08. Dezember 2011
Reminder: Roche conference call for investors and analysts from SABCS 2011
CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive ... mehr

08. Dezember 2011
Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer
Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine ... mehr

01. Dezember 2011
Roche’s cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark
New Test allows identification of lung cancer patients who may benefit from early treatment with EGFR inhibitors. Roche announced ... mehr

30. November 2011
Roche conference call for investors and analysts from SABCS 2011
CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive ... mehr

30. November 2011
Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium
Roche today announced that it will present results from studies of its investigational medicine pertuzumab in HER2-positive ... mehr

23. November 2011
Roche purchases shares in tender offer for Anadys Pharmaceuticals
Roche today announced that its wholly owned subsidiary Bryce Acquisition Corporation has accepted for payment all shares validly ... mehr

18. November 2011
FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
U.S. Food and Drug Administration (FDA) Commissioner revokes approval of Avastin for treatment of metastatic breast cancer ... mehr

09. November 2011
FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s New Drug ... mehr

31. Oktober 2011
Reminder: Invitation to Late-stage pipeline event Monday, 7 November 2011
The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on ... mehr

20. Oktober 2011
Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years
Phase III trials underway to investigate ocrelizumab in two forms of MS. Roche today announced 96-week results from a Phase ... mehr

18. Oktober 2011
Roche reports positive study of Herceptin given by subcutaneous injection
Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin. Roche today announced ... mehr

17. Oktober 2011
Roche signs definitive agreement to acquire Anadys Pharmaceuticals
Roche and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that the two companies have entered into a definitive ... mehr

13. Oktober 2011
Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches
Group sales rise 2% at CER (-12% in Swiss francs; +7% in US dollars), excluding Tamiflu; Significant foreign exchange impact ... mehr

11. Oktober 2011
Invitation to Late-stage pipeline event Monday, 7 November 2011
The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on ... mehr

06. Oktober 2011
Reminder: Invitation to Roche's Third Quarter Sales 2011 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

30. September 2011
Roche wins first major public tender in Europe to screen women for cervical cancer with its Human Papillomavirus test
Roche announced today that it has been awarded an exclusive contract by Karolinska University Hospital in Stockholm, Sweden, ... mehr

29. September 2011
Roche receives clearance from the U.S. Food and Drug Administration for new generation of Accu-Chek Aviva Plus Test Strips for people with diabetes
Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Aviva ... mehr

26. September 2011
Anti-Cancer Agent, Avastin Obtained Approval for Additional Indication and Dosage and Administration of “Inoperable or Recurrent Breast Cancer“
Please find attached a press release by Chugai. mehr

26. September 2011
Peginterferon alfa-2a “Pegasys” Approved for Additional Indication of “Chronic Active Hepatitis B”
Please find attached a press release by Chugai mehr

25. September 2011
Roche's investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer
Roche today announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic ... mehr

24. September 2011
Avastin and pemetrexed combination gives lung cancer patients significantly more time without their disease progressing
Roche today announced that AVAPERL, a phase III study evaluating the combination of Avastin® (bevacizumab) and chemotherapy ... mehr

23. September 2011
Roche's Avastin receives positive opinion from European authority for the treatment of women with newly diagnosed advanced ovarian cancer
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the ... mehr

19. September 2011
Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress
Roche today announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European ... mehr

14. September 2011
Invitation to Roche's Third Quarter Sales 2011 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

13. September 2011
Reminder Investor Day: Roche Diagnostics Enabling Personalised Healthcare
We are pleased to invite you to our Roche Diagnostics Investor Day on 21 September at 14:30 BST / 15:30 CET / 9:30 AM EDT ... mehr

08. September 2011
Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year
Reinforces commitment to creating long-term value for all stakeholders. Roche announced today that it has been recognized ... mehr

02. September 2011
Chugai Initiates Clinical Trials for Multiple In-Licensed Compounds
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, “Chugai”)] ... mehr

01. September 2011
Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer
Personalised Healthcare strategy allows to identify lung cancer patients who benefit from early treatment with Tarceva. Roche ... mehr

29. August 2011
Dalcetrapib phase II studies support the safety profile and potential for slowing of plaque progression in patients at risk of coronary heart disease
Roche announced today results from two exploratory mechanistic Phase IIb studies investigating dalcetrapib’s effects ... mehr

25. August 2011
Roche Investor Science Call from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE
We kindly invite investors and analysts to participate in a conference call that will be held during the European Society ... mehr

22. August 2011
Investor Day: Roche Diagnostics Enabling Personalised Healthcare
We are pleased to invite you to our Roche Diagnostics Investor Day on 21 September at 14:30 BST / 15:30 CET / 9:30 AM EDT ... mehr

17. August 2011
FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of ... mehr

15. August 2011
Roche Investor Science Event from ESC 2011
Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE - Monday, 29 August 2011, Paris, ... mehr

15. August 2011
Chugai to In-license BRAF Inhibitor Vemurafenib
Dear Investor, Please find attached a press release by Chugai. mehr

04. August 2011
Roche's investigational treatment for asthma met its primary endpoint in a phase II study
Roche today announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody ... mehr

03. August 2011
Roche’s RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis
Medicine offers new treatment option for Systemic Juvenile Idiopathic Arthritis (sJIA). Roche announced today that the European ... mehr

22. Juli 2011
Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the ... mehr

22. Juli 2011
Full reconciliation of Chugai interim results into IFRS
Results of Chugai as consolidated by the Roche Group. Following the publication of Chugai’s official 2011 interim results, ... mehr

21. Juli 2011
Roche on track - full year earnings outlook increased
Group sales stable in local currencies. Excluding Tamiflu, Group sales up 2% and Pharmaceuticals Division sales up 1%; Diagnostics ... mehr

19. Juli 2011
Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra" Subcutaneous Injection Demonstrates Efficacy in Rheumatoid Arthritis in Phase III Clinical Study
Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. mehr

19. Juli 2011
Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing
Roche announced today that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), ... mehr

15. Juli 2011
Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse
Roche today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint. mehr

14. Juli 2011
Reminder: Invitation to Roche's Half Year Results for 2011
Roche will publish its Half Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 21st July at 7:00 CET ... mehr

14. Juli 2011
Roche researchers develop antibody that crosses the blood-brain barrier more efficiently
Roche announced today two research publications from its Early Development unit gRED outlining how a new technology successfully ... mehr

01. Juli 2011
Chronic Hepatitis C Treatment, Pegasys, and Antiviral Drug, Copegus, Obtained Approval for Additional Indication of Compensated Liver Cirrhosis Related to Hepatitis C
Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. mehr

01. Juli 2011
Anti-Cancer Agent, Tarceva Obtained Approval for Additional Indication of Pancreatic Cancer Not Amenable to Curative Resection and Measures for Proper Use
Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. mehr

30. Juni 2011
Roche provides update from FDA hearing on Avastin for metastatic breast cancer
FDA Commissioner to Make Final Decision at a Later Date. Roche announced today that, during a U.S. Food and Drug Administration ... mehr

30. Juni 2011
Roche's Avastin receives broader EU label for women with metastatic breast cancer
Expanded label allows combination with Xeloda or paclitaxel in first-line setting. Roche announced today that the European ... mehr

29. Juni 2011
Two pivotal phase III Lucentis studies showed patients with diabetic macular edema experienced significant improvements in vision and fewer developed more advanced retinopathy
Two-Year Data from RISE and RIDE studies presented at the American Diabetes Association Annual Scientific Sessions. Genentech, ... mehr

24. Juni 2011
Invitation to Roche's Half Year Results for 2011
Roche will publish its Half Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 21st July at 7:00 CET ... mehr

20. Juni 2011
Pivotal study showed vismodegib helped shrink tumours or heal lesions in people with rare form of advanced skin cancer
Roche announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal ... mehr

05. Juni 2011
Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations
Roche’s Personalised Healthcare approach demonstrated through vemurafenib and its investigational companion diagnostic, ... mehr

04. Juni 2011
Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer
Phase III OCEANS results add to the growing body of evidence supporting Avastin’s potential role in ovarian cancer. ... mehr

03. Juni 2011
Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse
Roche today announced results of EURTAC, the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically ... mehr

02. Juni 2011
Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer
Roche today announced that it has entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) ... mehr

27. Mai 2011
Roche Analyst Event at ASCO 2011
Analyst briefing on data presented at ASCO: Sunday, 5th June 2011. We are pleased to invite you to an analyst briefing to ... mehr

26. Mai 2011
RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis
New study confirms RoACTEMRA is effective when used on its own for people who do not respond to methotrexate. Roche today ... mehr

20. Mai 2011
RoActemra offers a new option for children living with a rare and severe form of arthritis
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an ... mehr

20. Mai 2011
Roche ASCO Planner
Roche and Genentech will present a large number of abstracts on their broad oncology portfolio at the American Society of ... mehr

19. Mai 2011
MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse
Roche today announced final results from a randomised, multicentre, double-blind Phase II study with its investigational personalised ... mehr

18. Mai 2011
Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO
Progress in advanced skin and lung cancers through personalised healthcare. New Phase III data for Avastin in ovarian cancer ... mehr

17. Mai 2011
Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C
Roche announced today that it has entered into agreements with Merck, known as MSD outside the United States, through their ... mehr

11. Mai 2011
New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer
Roche today announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food ... mehr

05. Mai 2011
Roche Analyst Event at ASCO 2011
Analyst briefing on data presented at ASCO: Sunday, 5 June 2011 We are pleased to invite you to an analyst briefing to discuss ... mehr

26. April 2011
Long-Acting Erythropoiesis Stimulating Agent, Mircera Injection Syringe, approved in Japan
Press release by Chugai mehr

20. April 2011
FDA approves Rituxan/MabThera plus a steroid for use in severe forms of vasculitis
Roche and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab), ... mehr

20. April 2011
FDA Approves Roche’s HPV Test for Identifying Women at Highest Risk for Cervical Cancer
Roche announced today that the US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test ... mehr

19. April 2011
Diversity of approaches in research continues to empower scientific excellence at Roche
Roche announced today that the Group's strong scientific publication track record from Genentech's and Roche's ... mehr

18. April 2011
FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
Medicine offers a new option for children living with a rare and severe form of arthritis. Roche today announced that the ... mehr

15. April 2011
Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe
Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients. Roche ... mehr

14. April 2011
Roche Group's first-quarter 2011 sales on track for full-year targets - positive results in seven key clinical trials
Group sales stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs in first three ... mehr

07. April 2011
Reminder: Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011
Roche will publish its Sales Results for the 1st Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

07. April 2011
Roche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer
Roche today announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic ... mehr

01. April 2011
Dalcetrapib Phase II studies dal-VESSEL and dal-PLAQUE show encouraging results
Roche announced today that the results from two exploratory Phase IIb studies, dal-VESSEL and dal-PLAQUE, further support ... mehr

28. März 2011
Second Lucentis Phase III study meets primary endpoint for improved vision in patients with diabetic macular edema (DME)
Results consistent with data released last month showing patients with DME who received Lucentis achieved significant improvement ... mehr

21. März 2011
Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma
Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib ... mehr

15. März 2011
Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011
Roche will publish its Sales Results for the 1st Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

15. März 2011
Roche acquires PVT to strengthen laboratory automation in clinical diagnostics
Roche announced today the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, ... mehr

10. März 2011
Phase III study of Lucentis showed rapid vision improvements sustained for two years in patients with diabetic macular edema
Roche today announced that two-year results from a pivotal Phase III trial (RISE) showed patients with diabetic macular edema ... mehr

10. März 2011
Herceptin approved in Japan for additional indication of advanced or recurrent gastric cancer overexpressing HER2, which is not amenable to curative resection
mehr

02. März 2011
European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer
Roche announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will ... mehr

01. März 2011
Roche Annual General Meeting: dividend raised by 10%
Roche's Annual General Meeting, which was held today in Basel, has approved all of the Board of Directors' proposals. ... mehr

25. Februar 2011
Pivotal Study Validates Roche’s cobas HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer
Roche announced that a study published online today in the American Journal of Clinical Pathology demonstrated the ability ... mehr

23. Februar 2011
Xeloda approved in Japan for Additional Indication of Advanced or Recurrent Gastric Cancer, which is Not Amenable to Curative Resection
Dear Investor, Please find attached a press release by Chugai: http://www.roche.com/inv-update-2011-02-23-annex.pdf Do not ... mehr

16. Februar 2011
Roche initiates phase III study investigating infusion-free administration of MabThera for patients with non-Hodgkin's lymphoma
Roche today announced the initiation of a phase III study to investigate a subcutaneous formulation of MabThera (rituximab) ... mehr

14. Februar 2011
Lucentis Phase III study meets primary endpoint for improving vision in patients with diabetic macular edema (DME)
Roche today announced that one of two Phase III studies evaluating monthly Lucentis (ranibizumab injection) in patients with ... mehr

08. Februar 2011
Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer
Roche announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin ... mehr

02. Februar 2011
Full reconciliation of Chugai 2010 results into IFRS
Following the publication of Chugai's official 2010 results, Roche offers this investor update which reconciles these ... mehr

02. Februar 2011
Solid overall results
Mid-single digit sales growth in local currencies excluding Tamiflu - Strong profit growth - Promising late stage pharmaceutical ... mehr

31. Januar 2011
FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) as a maintenance ... mehr

28. Januar 2011
Early successful readout of Tarceva study in a distinct form of lung cancer
Roche today announced that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped ... mehr

19. Januar 2011
Reminder: Invitation to Roche's Full Year Results for 2010
Roche will publish its Full Year Results for 2010 prior to the opening of the Swiss Stock Exchange on 2 February at 7:00 CET ... mehr

19. Januar 2011
Roche personalized investigational medicine shows survival benefit in advanced skin cancer
Roche today announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant ... mehr

17. Januar 2011
Changes to the Roche Corporate Executive Committee
Erich Hunziker (born 1953), Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive ... mehr

05. Januar 2011
FDA grants supplemental approval for ACTEMRA
Roche today announced that the United States Food and Drug Administration has extended the ACTEMRA label to include inhibition ... mehr

04. Januar 2011
Roche's Full Year Results for 2010
Roche will publish its Full Year Results for 2010 prior to the opening of the Swiss Stock Exchange on 2 February at 7:00 CET ... mehr